title: Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
abstract: The mechanism of doxorubicin is compared with that of doxazolidine, a doxorubicin-formaldehyde conjugate. The IC(50) for growth inhibition of 67 human cancer cell lines, but not cardiomyocytes, is 32-fold lower with doxazolidine than with doxorubicin. Growth inhibition by doxazolidine correlates better with growth inhibition by DNA cross-linking agents than with growth inhibition by doxorubicin. Doxorubicin induces G2/M arrest in HCT-116 colon cancer cells and HL-60 leukemia cells through a well-documented topoisomerase II dependent mechanism. Doxazolidine fails to induce a G2/M arrest in HCT-116 cells but induces apoptosis 4-fold better than doxorubicin. The IC(50) for doxazolidine growth inhibition of HL-60/MX2 cells, a topoisomerase II deficient derivative of HL-60 cells, is 1420-fold lower than the IC(50) for doxorubicin, and doxazolidine induces apoptosis 15-fold better. Further, doxazolidine has little effect in a topoisomerase II activity assay. These data indicate that doxorubicin and doxazolidine induce apoptosis via different mechanisms and doxazolidine cytotoxicity is topoisomerase II independent.
authors: Department of Chemistry and Biochemistry, University of Colorado, Boulder, Colorado 80309, USA.
authors: Brian T
authors: BT
authors: Kalet
authors: Meagan B
authors: MB
authors: McBryde
authors: Joaquin M
authors: JM
authors: Espinosa
authors: Tad H
authors: TH
authors: Koch
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis; D002453:Cell Cycle / Q000187:drug effects; D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004250:DNA Topoisomerases, Type II / Q000235:genetics / Q000502:physiology*; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D005557:Formaldehyde / Q000031:analogs & derivatives* / Q000494:pharmacology*; D006801:Humans; D008958:Models, Molecular; D032383:Myocytes, Cardiac / Q000166:cytology / Q000187:drug effects; D059005:Topoisomerase II Inhibitors
chemical_list: D000970:Antineoplastic Agents; D059005:Topoisomerase II Inhibitors; D005557:Formaldehyde; D004317:Doxorubicin; D004250:DNA Topoisomerases, Type II
references: Nucleic Acids Res. 1994 Jun 25;22(12):2296-303
references: 8036157
references: Cancer Chemother Rep. 1969 Feb;53(1):33-7
references: 5772652
references: N Engl J Med. 1981 Jul 16;305(3):139-53
references: 7017406
references: Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11561-5
references: 9751705
references: Annu Rev Biochem. 1989;58:351-75
references: 2549853
references: In Vitro. 1978 Nov;14(11):911-5
references: 730202
references: Biochem Pharmacol. 1994 Jun 15;47(12):2269-78
references: 8031321
references: Biochemistry. 1991 Apr 23;30(16):3812-5
references: 2018756
references: Anal Biochem. 1986 Nov 15;159(1):109-13
references: 3812988
references: IUBMB Life. 2005 Feb;57(2):73-81
references: 16036566
references: Cancer Res. 2006 May 1;66(9):4863-71
references: 16651442
references: J Med Chem. 1997 Apr 11;40(8):1276-86
references: 9111302
references: J Med Chem. 1997 Aug 1;40(16):2452-61
references: 9258351
references: Chem Res Toxicol. 1997 Sep;10(9):953-61
references: 9305576
references: Chem Rev. 1998 Dec 17;98(8):2723-2796
references: 11848977
references: Bioorg Med Chem. 2007 Feb 15;15(4):1651-8
references: 17194596
references: J Med Chem. 1986 Jul;29(7):1225-30
references: 3806572
references: J Liposome Res. 2006;16(3):175-83
references: 16952872
references: J Antibiot (Tokyo). 1988 Mar;41(3):404-8
references: 3163334
references: Prog Cell Cycle Res. 2003;5:295-300
references: 14593724
references: J Immunol Methods. 1983 Dec 16;65(1-2):55-63
references: 6606682
references: J Clin Invest. 1999 Aug;104(3):263-9
references: 10430607
references: Anal Chem. 2001 Jul 1;73(13):2992-7
references: 11467545
references: Biochemistry. 1994 Apr 19;33(15):4632-8
references: 8161519
references: Mini Rev Med Chem. 2005 May;5(5):449-67
references: 15892687
references: Pharmacol Rev. 2004 Jun;56(2):185-229
references: 15169927
references: Cancer Res. 1995 Apr 15;55(8):1707-16
references: 7712479
references: J Med Chem. 2006 Nov 30;49(24):7002-12
references: 17125253
references: Anticancer Res. 1999 Mar-Apr;19(2A):1201-8
references: 10368676
references: Cancer Res. 2002 Dec 1;62(23):6938-43
references: 12460910
references: Anticancer Res. 2001 Jul-Aug;21(4A):2753-60
references: 11724351
references: Mol Cancer Ther. 2004 Dec;3(12):1593-604
references: 15634653
references: J Biol Chem. 1983 Dec 25;258(24):15365-70
references: 6317692
references: Clin Cancer Res. 2005 Feb 15;11(4):1608-17
references: 15746066
references: J Med Chem. 2004 Dec 16;47(26):6509-18
references: 15588086
references: Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2464-9
references: 8637897
references: Anal Biochem. 1990 Jun;187(2):262-7
references: 2382827
references: Acta Crystallogr D Biol Crystallogr. 1999 Sep;55(Pt 9):1516-23
references: 10489446
references: J Med Chem. 1992 Aug 21;35(17):3208-14
references: 1354750
references: J Med Chem. 2005 Dec 1;48(24):7648-57
references: 16302805
references: Chem Res Toxicol. 2000 Jun;13(6):509-16
references: 10858324